Temsirolimus is a antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR. It was developed by Wyeth Pharmaceuticals under the trade name Torisel.
- Mechanism
- Curator reviewed
Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.
- Primary indication
- For the treatment of renal cell carcinoma (RCC).Curator reviewed · 1 structured indication
- Formula / weight
- C56H87NO16 · 1030.2871 g/mol (avg)
- First approval
- Canada, 2010 · United States, 2007 · European Union, 2016
- Code names
- CCI-779 · WAY-CCI 779
- Brand names
Resolves to
CBPNZQVSJQDFBE-FUXHJELOSA-NSMILESOCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OCWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Temsirolimus, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account